3,4-dihydroxypyridine has been researched along with deferiprone in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| el-Jammal, A; Howell, PL; Li, N; Templeton, DM; Turner, MA | 1 |
| Dobbin, PS; Hall, AD; Hider, RC; Porter, JB; Sarpong, P; Taylor, PD; van der Helm, D; Xiao, G | 1 |
| Hider, RC; Khodr, HH; Liu, ZD; Lu, SL | 1 |
| Chaves, S; Gano, L; Gil, M; Santos, MA | 1 |
| Balzarini, J; Barral, K; Camplo, M; De Clercq, E; Hider, RC; Neyts, J | 1 |
| Bansal, S; Hider, R; Kong, XL; Lu, Z; Xie, YY; Zhou, T | 1 |
6 other study(ies) available for 3,4-dihydroxypyridine and deferiprone
| Article | Year |
|---|---|
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
Topics: Antithyroid Agents; Copper; Deferiprone; Iron Chelating Agents; Ligands; Potentiometry; Pyridones; Spectrophotometry | 1994 |
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
Topics: Administration, Oral; Animals; Crystallography; Deferoxamine; Horses; Humans; Iron; Iron Chelating Agents; Liver; Mice; Pyridones; Rats; Stereoisomerism; Structure-Activity Relationship | 1993 |
Design, synthesis and evaluation of N-basic substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotrophic potential.
Topics: Alkalies; Animals; Biological Transport; Chemical Phenomena; Chemistry, Physical; Deferiprone; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation; Ferritins; Hydrogen-Ion Concentration; Iron Chelating Agents; Iron Radioisotopes; Ligands; Liver; Lysosomes; Male; Pyridones; Rats; Rats, Wistar | 2000 |
Bifunctional 3-hydroxy-4-pyridinone derivatives as potential pharmaceuticals: synthesis, complexation with Fe(III), Al(III) and Ga(III) and in vivo evaluation with 67Ga.
Topics: Aluminum; Animals; Deferiprone; Drug Design; Gallium; Gallium Radioisotopes; Iron; Mice; Molecular Structure; Pyridones; Tissue Distribution | 2005 |
Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives.
Topics: Animals; Antiviral Agents; Cell Line; Cell Proliferation; Chlorocebus aethiops; Deferiprone; HeLa Cells; Herpesvirus 1, Human; Herpesvirus 2, Human; HIV-1; HIV-2; Humans; Ligands; Microbial Sensitivity Tests; Molecular Structure; Nucleosides; Pyridones; Structure-Activity Relationship; Vero Cells | 2006 |
Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.
Topics: Administration, Oral; Deferiprone; Humans; Hydrogen-Ion Concentration; Iron Chelating Agents; Microsomes, Liver; Pyridones | 2016 |